CD8A and neoplasm: Administeringthe scFv-mPAC with an antigen-conjugated LFN activatedin vivo immune responses through the recruitment of CD8+ T cells and demonstrates that the scFv-mPAC/LFN systemtargets DCs with tumor-specific antigens.